multilevel modeling in cardiac drug utilization research

32
Multilevel Modeling in Cardiac Drug Utilization Research

Upload: alannah-stewart

Post on 18-Dec-2015

229 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: Multilevel Modeling in Cardiac Drug Utilization Research

Multilevel Modeling in Cardiac Drug Utilization Research

Page 2: Multilevel Modeling in Cardiac Drug Utilization Research

Outline

PROC GLIMMIX introductionPROC GLIMMIX introduction Cardiac drug utilization Cardiac drug utilization

research research

using multilevel models.using multilevel models.

Page 3: Multilevel Modeling in Cardiac Drug Utilization Research

Multilevel data

Multilevel data are common in Multilevel data are common in observational study in social observational study in social science, health care field. science, health care field.

Clinical trials carried out in Clinical trials carried out in serveral random selected center serveral random selected center or groups of subjects create data or groups of subjects create data hierarchieshierarchies

Page 4: Multilevel Modeling in Cardiac Drug Utilization Research

The Research Question

Investigate clinical and non-clinical factors Investigate clinical and non-clinical factors associated with prescription of cardiac drugs associated with prescription of cardiac drugs for patients discharged after catheterization.for patients discharged after catheterization.

Page 5: Multilevel Modeling in Cardiac Drug Utilization Research

Heart Catheterization

Page 6: Multilevel Modeling in Cardiac Drug Utilization Research

Inclusion/Exclusion Criteria

Include All patients underwent Include All patients underwent the 1the 1stst CATH from 1999/07 to CATH from 1999/07 to 2002/10 2002/10

Exclude patients with age<20, Exclude patients with age<20, non-BC patients, prior CABG or non-BC patients, prior CABG or PCI, in hospital death, PCI, in hospital death, discharged to extended caredischarged to extended care

Exclude patients with normal Exclude patients with normal angiogramangiogram

Page 7: Multilevel Modeling in Cardiac Drug Utilization Research

Drugs of interests

ACE Inhibitor ACE Inhibitor Beta BlockerBeta Blocker StatinStatin Optimum drugOptimum drug

Page 8: Multilevel Modeling in Cardiac Drug Utilization Research

Factor of Interest

Patient level: Patient level: sex, age, extent of disease (blockage), prior drug, sex, age, extent of disease (blockage), prior drug,

ejection fraction, prior MI, DM, renal, HPD, HTN, ejection fraction, prior MI, DM, renal, HPD, HTN, PVD, CVA, CHF, COPD, liver disease, urgency, PVD, CVA, CHF, COPD, liver disease, urgency, indication, cardiac re-hospitalization, transfer indication, cardiac re-hospitalization, transfer history, length of hospital stay, revascularization, history, length of hospital stay, revascularization,

Hospital level:Hospital level: teaching hospital teaching hospital Physician level:Physician level: year of service, volume of year of service, volume of

serviceservice Neighbourhood level: Neighbourhood level: Median family income, univeristy education rate, Median family income, univeristy education rate,

immigration rateimmigration rate

Page 9: Multilevel Modeling in Cardiac Drug Utilization Research

Assumption

Admission Discharge

1st Catheterization120 days

Page 10: Multilevel Modeling in Cardiac Drug Utilization Research

Data Structure

The data set consists 22847 patients The data set consists 22847 patients Hospital level: Patients discharged from 67 BC Hospital level: Patients discharged from 67 BC

hospitals with hospital cluster size from 1 to 4403 hospitals with hospital cluster size from 1 to 4403 patients; 97% patients discharged from hospital patients; 97% patients discharged from hospital with cluster size>100. with cluster size>100.

Physician level: Patients discharged by 1059 Physician level: Patients discharged by 1059 physicians (with anywhere between 1 to 785); 72% physicians (with anywhere between 1 to 785); 72% patients discharged by physician with cluster size patients discharged by physician with cluster size >100).>100).

Census tract level: Patients came from 695 census Census tract level: Patients came from 695 census tract with census tract cluster size from 1 to 342, tract with census tract cluster size from 1 to 342, 73% patients came from census tract with cluster 73% patients came from census tract with cluster size>30.size>30.

Page 11: Multilevel Modeling in Cardiac Drug Utilization Research

Data Structure

Patient

Hospital

Physician Neighbourhoods

Page 12: Multilevel Modeling in Cardiac Drug Utilization Research

Cross random intercept model

yyi i ~ Bernouilli ( ~ Bernouilli ( ππi i ))

Logit(Logit(ππii) = ) = ββ0i0i + + ββ11 x x1i1i

ββ0i0i = = ββ0 0 + + δδhosp(i)hosp(i)(2) (2) + + δδdoc(i)doc(i)

(3) (3) + + δδtract(i)tract(i)(4) (4)

Where i indexes the patient i, and hosp(i), Where i indexes the patient i, and hosp(i), doc(i), and tract(i) are functions that doc(i), and tract(i) are functions that return the unit number of the hospital, return the unit number of the hospital, doctor, and census tract, respectively, doctor, and census tract, respectively, that patient i belong to.that patient i belong to.

Page 13: Multilevel Modeling in Cardiac Drug Utilization Research

Cross random intercept model

yyi i ~ Bernouilli ( ~ Bernouilli ( ππi i ))

Logit(Logit(ππii) =) =ββ0 0 + + ββ11 x x1i1i + + δδhosp(i)hosp(i)(2) (2) + + δδdoc(i)doc(i)

(3) (3) + + δδtract(i)tract(i)(4) (4)

δδhosp(i)hosp(i)(2) (2) ~ N (0, ~ N (0, σσδδ(2)(2)

22 ) )

δδdoc(i)doc(i)(3) (3) ~ N (0, ~ N (0, σσδδ(3)(3)

22 ) )

δδtract(i)tract(i)(4) (4) ~ N (0, ~ N (0, σσδδ(4)(4)

22 ) )

Page 14: Multilevel Modeling in Cardiac Drug Utilization Research

Allow coefficient to vary across the classification

Suppose Suppose ββ1i1i represent heart failure, we represent heart failure, we

want to know whether the impact of want to know whether the impact of heart failure vary across the hospital heart failure vary across the hospital classification, we would use cross classification, we would use cross random coefficient model to investigate random coefficient model to investigate that.that.

Page 15: Multilevel Modeling in Cardiac Drug Utilization Research

Cross random coefficient model

yyi i ~ Bernouilli ( ~ Bernouilli ( ππi i ))

Logit(Logit(ππii) = ) = ββ0i0i + + ββ1i1i x x1i1i

ββ0i0i = = ββ0 0 + + δδhosp(i),0hosp(i),0(2) (2) + + δδdoc(i)doc(i)

(3) (3) + + δδtract(i)tract(i)(4) (4)

ββ1i1i = = ββ1 1 + + δδhosp(i),1hosp(i),1(2) (2)

Where Where δδhosp(i),0hosp(i),0(2) and (2) and δδhosp(i),1hosp(i),1

(2) (2) representing the representing the

hospital random intercept effects hospital random intercept effects

and random slope effects, respectively. and random slope effects, respectively.

Page 16: Multilevel Modeling in Cardiac Drug Utilization Research

Which procedure to use?

ModelModel Response typeResponse type Random effectsRandom effects

LOGISTILOGISTICC

BinaryBinary NONO

GLMGLM IntervalInterval NONO

GENMOGENMODD

Categorical, Categorical, IntervalInterval

NONO

MIXEDMIXED IntervalInterval YesYes

NLMIXENLMIXEDD

Categorical, Categorical, IntervalInterval

Yes, but not suitable for Yes, but not suitable for complex random effectscomplex random effects

GLIMMIXGLIMMIX Categorical, Categorical, IntervalInterval

Yes, suitable for Yes, suitable for complex random effectscomplex random effects

Page 17: Multilevel Modeling in Cardiac Drug Utilization Research

Where to get proc glimmix

The glimmix procedure is a new The glimmix procedure is a new procedure in SAS/STAT software. procedure in SAS/STAT software. It is an add-on for the SAS/STAT It is an add-on for the SAS/STAT product in SAS 9.1 on either the product in SAS 9.1 on either the Windows or Linux platform. It is Windows or Linux platform. It is currently downloadable for the currently downloadable for the SAS 9.1 release from software SAS 9.1 release from software downloads at support.sas.com.downloads at support.sas.com.

Page 18: Multilevel Modeling in Cardiac Drug Utilization Research

Two level glimmix

procproc glimmixglimmix data=glim_dataF IC=Q; data=glim_dataF IC=Q;

classclass sex ageGP65 dis_hosp ; sex ageGP65 dis_hosp ;

modelmodel drug(event= drug(event='YES''YES')=sex )=sex ageGP65/solution dist=binary ageGP65/solution dist=binary link=logit ddfm=bw oddsratio;link=logit ddfm=bw oddsratio;

randomrandom int / subject=dis_hosp; int / subject=dis_hosp;

runrun;;

Page 19: Multilevel Modeling in Cardiac Drug Utilization Research

Three level glimmix

procproc glimmixglimmix data=glim_dataF IC=Q; data=glim_dataF IC=Q;

classclass sex ageGP65 dis_hosp dis_phy; sex ageGP65 dis_hosp dis_phy;

modelmodel drug(event= drug(event='YES''YES')=sex )=sex ageGP65/solution dist=binary link=logit ageGP65/solution dist=binary link=logit ddfm=bw oddsratio;ddfm=bw oddsratio;

randomrandom int / subject=dis_phy(dis_hosp); int / subject=dis_phy(dis_hosp);

runrun;;

Page 20: Multilevel Modeling in Cardiac Drug Utilization Research

Order in the class statement

Value of ORDER= Levels Sorted By

DATA order of appearance in the input data set

FORMATTED external formatted value, except for numeric variables with no explicit format, which are sorted by their unformatted (internal) value

FREQ descending frequency count; levels with the most observations come first in the order

INTERNAL unformatted value

Page 21: Multilevel Modeling in Cardiac Drug Utilization Research

Proc glimmix

AdvantageAdvantage• Allows multiple random effects, nested Allows multiple random effects, nested

and crossed random effectsand crossed random effects• Allows subject-specific and population-Allows subject-specific and population-

averaged inferenceaveraged inference• Allows nonnormal distribution of Allows nonnormal distribution of

responseresponse DisadvantageDisadvantage

• The absence of a true log likelihoodThe absence of a true log likelihood• The computation of cross effects model The computation of cross effects model

is time consumingis time consuming

Page 22: Multilevel Modeling in Cardiac Drug Utilization Research

Upcoming features in proc glimmix in SAS 9.2

The COVTEST statement for The COVTEST statement for likelihood-based testing and likelihood-based testing and confidence intervals for confidence intervals for covariance parameters.covariance parameters.

Better output format?Better output format?

Page 23: Multilevel Modeling in Cardiac Drug Utilization Research

Effects of ignoring Nested Structure

Covariance Estimates Hospital(SE) Physician(SE) Census Tract(SE)ACE Inhibitor Hospital 0.17(0.07)

Physician 0.32(0.06)Physician(Hospital) 0.14(0.06) 0.22(0.04)Physician(Hospital)*census tract 0.14(0.06) 0.22(0.04) 0.02(0.01)

Beta Blocker Hospital 0.18(0.07)Physician 0.26(0.04)Physician(Hospital) 0.19(0.07) 0.10(0.02)Physician(Hospital)*census tract 0.19(0.07) 0.10(0.02) 0

Statin Hospital 0.19(0.07)Physician 0.39(0.06)Physician(Hospital) 0.20(0.08) 0.21(0.04)Physician(Hospital)*census tract 0.19(0.07) 0.20(0.04) 0.02(0.01)

Optimum Rx Hospital 0.20(0.07)Physician 0.24(0.04)Physician(Hospital) 0.20(0.07) 0.09(0.02)Physician(Hospital)*census tract 0.19(0.07) 0.10(0.02) 0.02(0.01)

Page 24: Multilevel Modeling in Cardiac Drug Utilization Research

Effects of ignoring Nested Structure

Ignoring the hospital hierarchy Ignoring the hospital hierarchy leads to inflation of physician leads to inflation of physician variance estimates drasticly variance estimates drasticly

Adding the cross effect of Adding the cross effect of census tract on hospital-census tract on hospital-physician nested hierarchy physician nested hierarchy doesn’t change the hospital doesn’t change the hospital and physician variance. and physician variance.

Page 25: Multilevel Modeling in Cardiac Drug Utilization Research

Does Teaching hospital help to explain the variation at hospital level?

Covariance Estimates Hospital(SE) Phyician(SE) census Tract(SE)ACE Ihibitor intercept model 0.11(0.04) 0.25(0.04) 0.03(0.01)

patient level variable model 0.14(0.06) 0.26(0.05) 0.02(0.01)Patient level variable +high level variable model 0.14(0.06) 0.22(0.04) 0.02 (0.01)

Beta Blocker intercept model 0.14(0.05) 0.11(0.02) 0.004(0.006)patient level variable model 0.17(0.07) 0.11(0.03) 0Patient level variable +high level variable model 0.19(0.07) 0.10(0.02) 0

Statin intercept model 0.14(0.05) 0.21(0.04) 0.04(0.01)patient level variable model 0.19(0.07) 0.20(0.04) 0.03(0.01)Patient level variable +high level variable model 0.19(0.07) 0.20(0.04) 0.02(0.01)

Optimum Rx intercept model 0.16(0.05) 0.14(0.02) 0.03(0.01)patient level model 0.18(0.06) 0.10(0.02) 0.02(0.01)Patient level variable +high level variable model 0.19(0.07) 0.10(0.02) 0.02(0.01)

Cross effects model

Page 26: Multilevel Modeling in Cardiac Drug Utilization Research

Does Teaching hospital help to explain the variation at hospital level?

Teaching hospital effect does Teaching hospital effect does not explain the variation at not explain the variation at hospital levelhospital level

Service years of physician and Service years of physician and physician service volume only physician service volume only explain very little of the explain very little of the variation at physician levelvariation at physician level

Page 27: Multilevel Modeling in Cardiac Drug Utilization Research

ACE Inhibitor single level LR vs. multilevel LR

1st row:: Single level LR results

2nd row: multilevel LR results

OR LowerCL UpperCLYears of service Q1 vs Q4 1.34 1.22 1.48

1.24 1.05 1.47Q2 vs Q4 0.91 0.83 1.01

0.87 0.74 1.03Q3 vs Q4 0.99 0.90 1.10

1.01 0.86 1.17

Volume of service Q1 vs Q4 0.68 0.61 0.77

0.72 0.60 0.86Q2 vs Q4 0.91 0.83 1.01

0.87 0.74 1.03Q3 vs Q4 0.83 0.75 0.91

0.92 0.79 1.06Teaching Hospital 1.39 1.28 1.51

1.20 0.68 2.13

Immigration Rate Q5 vs Q1 0.90 0.81 1.01

0.93 0.81 1.06Q4 vs Q1 1.00 0.90 1.12

1.04 0.92 1.19Q3 vs Q1 0.90 0.81 1.01

0.97 0.86 1.09Q2 vs Q1 0.94 0.84 1.04

0.97 0.86 1.09

Page 28: Multilevel Modeling in Cardiac Drug Utilization Research

Beta Blocker single level LR vs. multilevel LR

1st row:: Single level LR results

2nd row: multilevel LR results

OR LowerCL UpperCLYears of service Q1 vs Q4 1.19 1.08 1.30

1.16 1.01 1.35Q2 vs Q4 1.07 0.97 1.18

1.10 0.94 1.28Q3 vs Q4 0.97 0.88 1.07

1.08 0.94 1.24

Volume of service Q1 vs Q4 0.86 0.77 0.96

0.76 0.65 0.89Q2 vs Q4 0.82 0.74 0.90

0.78 0.68 0.91Q3 vs Q4 0.94 0.86 1.04

0.93 0.81 1.06Teaching Hospital 1.70 1.57 1.84

1.36 0.71 2.58

Immigration Rate Q5 vs Q1 0.91 0.81 1.02

0.93 0.82 1.06Q4 vs Q1 0.77 0.69 0.86

0.88 0.78 0.99Q3 vs Q1 0.86 0.78 0.96

0.97 0.87 1.08Q2 vs Q1 0.92 0.83 1.02

0.97 0.87 1.08

Page 29: Multilevel Modeling in Cardiac Drug Utilization Research

Statin single level LR vs. multilevel LR

1st row:: Single level LR results

2nd row: multilevel LR results

OR LowerCL UpperCL

Years of service Q1 vs Q4 1.31 1.18 1.45

1.16 0.98 1.38

Q2 vs Q4 1.18 1.06 1.32

1.17 0.98 1.39

Q3 vs Q4 1.20 1.08 1.33

1.14 0.97 1.33

Volume of service Q1 vs Q4 0.99 0.88 1.12

1.00 0.83 1.20

Q2 vs Q4 1.13 1.02 1.26

1.04 0.88 1.23

Q3 vs Q4 0.95 0.86 1.06

0.95 0.82 1.11

Teaching Hospital 0.97 0.89 1.06

1.03 0.53 1.98

Immigration Rate Q5 vs Q1 0.68 0.61 0.77

0.75 0.65 0.86

Q4 vs Q1 0.87 0.77 0.98

0.94 0.81 1.08

Q3 vs Q1 0.93 0.82 1.04

0.91 0.80 1.04

Q2 vs Q1 1.09 0.96 1.22

Page 30: Multilevel Modeling in Cardiac Drug Utilization Research

Optimum Rx single level LR vs. multilevel LR

1st row:: Single level LR results

2nd row: multilevel LR results

OR LowerCL UpperCLYears of service Q1 vs Q4 1.33 1.22 1.44

1.22 1.07 1.38Q2 vs Q4 1.13 1.04 1.23

1.11 0.97 1.27Q3 vs Q4 0.99 0.91 1.07

1.08 0.95 1.22

Volume of service Q1 vs Q4 0.86 0.78 0.95

0.83 0.72 0.96Q2 vs Q4 1.00 0.91 1.09

0.93 0.82 1.06Q3 vs Q4 0.90 0.83 0.98

0.92 0.82 1.04Teaching Hospital 1.42 1.32 1.52

1.28 0.68 2.42Immigration Rate Q5 vs Q1 0.77 0.70 0.84

0.84 0.75 0.94Q4 vs Q1 0.86 0.78 0.94

0.98 0.88 1.10Q3 vs Q1 0.86 0.78 0.94

0.95 0.85 1.06Q2 vs Q1 0.93 0.85 1.02

0.97 0.88 1.08

Page 31: Multilevel Modeling in Cardiac Drug Utilization Research

Implication of the results

Compared to the cross effects Compared to the cross effects models, the standard errors of models, the standard errors of teaching hospital effect from the teaching hospital effect from the single-level logistic regression are single-level logistic regression are much smaller and lead to an invalid much smaller and lead to an invalid finding of significant teaching finding of significant teaching hospital effect.hospital effect.

Between census tract variance is Between census tract variance is fairly small. We keep the census fairly small. We keep the census tract random effects in the model as tract random effects in the model as we want to examine the influence of we want to examine the influence of immigration rate on drug utilization.immigration rate on drug utilization.

Page 32: Multilevel Modeling in Cardiac Drug Utilization Research

Reference

Judith D.Singer. Using SAS PROC MIXED to fit Judith D.Singer. Using SAS PROC MIXED to fit multilevel models, Hierarchical models, and multilevel models, Hierarchical models, and individual growth models. individual growth models. Journal of Educational Journal of Educational and Behavioral Statistics 1998; 24, 323-355and Behavioral Statistics 1998; 24, 323-355

Jone Rasbash , William Brown. Non-hierarchical Jone Rasbash , William Brown. Non-hierarchical multilevel models. multilevel models.

Tony Blakely, S V Subramanian. Multilevel Studies. Tony Blakely, S V Subramanian. Multilevel Studies. In Oakes M, Kaufman J, eds, Methods for social In Oakes M, Kaufman J, eds, Methods for social epidemiology, Jossey Bass: San Francisco. 2005: in epidemiology, Jossey Bass: San Francisco. 2005: in press.press.